Plasma ADAMTS-13 activity in proliferative lupus nephritis: a large cohort study from China

Abstract

Objectives

The aim of this study was to investigate plasma ADAMTS-13 activity in patients with proliferative lupus nephritis and to evaluate the role of clinical, laboratory and pathological features, especially the vascular lesions in lupus nephritis.

Methods

Plasma samples from 163 class III and IV lupus nephritis patients confirmed by biopsy examinations and 98 normal controls were collected. ADAMTS-13 activity was evaluated by a residual collagen binding assay. IgG autoantibodies against ADAMTS-13 were detected by ELISA using recombinant ADAMTS-13 as a solid-phase ligand. Levels of vWF were measured by ELISA. Their associations with clinical, laboratory and pathological features were further assessed.

Results

Plasma ADAMTS-13 activity in lupus nephritis patients was significantly lower than that in normal controls (84 ± 21% vs. 90 ± 13%, p = 0.005). IgG ADAMTS-13 autoantibodies were detected in only three patients. The plasma level of vWF was significantly higher in the lupus nephritis group than in normal controls (1.00 ± 0.79 vs. 0.70 ± 0.30, p = 0.025). Plasma ADAMTS-13 activity was negatively correlated with the level of serum creatinine and proteinuria (r = –0.354, p < 0.001; r = –0.200, p = 0.011, respectively). Patients with a higher level of ADAMTS-13 activity had significantly higher levels of factor H (401.51 ± 183.01 µg/ml vs. 239.02 ± 155.45 µg/ml, p = 0.005). Plasma ADAMTS-13 activity was negatively associated with total pathological AI scores (r = –0.326, p < 0.001), endocapillary hypercellularity (r = –0.419, p < 0.001), cellular crescents (r = –0.274, p < 0.001), subendothelial hyaline deposits (r = –0.266, p = 0.001), interstitial inflammatory cell infiltration (r = –0.304, P < 0.001), tubular atrophy (r = –0.199, p = 0.011), acute glomerular vascular lesions (r = –0.344, p < 0.001) and acute renal vascular lesions (r = –0.338, p < 0.001). No association was found between level of vWF and plasma ADAMTS-13 activity (r = 0.033, p = 0.671). Low level of ADAMTS-13 activity was a risk factor for renal outcomes (p = 0.039, HR = 0.047, 95% CI: 0.120–1.005).

Conclusions

Decreased ADAMTS-13 activity was found in patients with proliferative lupus nephritis, and plasma ADAMTS-13 activity was closely associated with renal injury indices, especially pathological vascular scores. The role of ADAMTS-13 in the disease remains to be further investigated.

Keywords

SLE lupus nephritis ADAMTS-13 thrombotic microangiopathy

Get full access to this article

View all access options for this article.

References

Barber

Herzenberg

Aghdassi

et al.

Evaluation of clinical outcomes and renal vascular pathology among patients with lupus. Clin J Am Soc Nephrol 2012; 7: 757–764.

Tan

et al.

Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions. Kidney Int 2013; 83: 715–723.

Furlan

Robles

Lammle

. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87: 4223–4234.

Tsai

. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87: 4235–4244.

Levy

Nichols

Lian

et al.

Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488–494.

Dong

Moake

Nolasco

et al.

ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002; 100: 4033–4039.

Lopez

Dong

. Cleavage of von Willebrand factor by ADAMTS-13 on endothelial cells. Semin Hematol 2004; 41: 15–23.

Chauhan

Motto

Lamb

et al.

Systemic antithrombotic effects of ADAMTS13. J Exp Med 2006; 203: 767–776.

Soejima

Nakagaki

. Interplay between ADAMTS13 and von Willebrand factor in inherited and acquired thrombotic microangiopathies. Semin Hematol 2005; 42: 56–62.

10.

Furlan

Robles

Galbusera

et al.

von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578–1584.

11.

Tsai

Lian

. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585–1594.

12.

Claus

Bockmeyer

Budde

et al.

Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure. Thromb Haemost 2009; 101: 239–247.

13.

Tan

Zhao

. Lupus nephritis combined with renal injury due to thrombotic thrombocytopaenic purpura-haemolytic uraemic syndrome. Nephrol Dial Transplant 2010; 25: 145–152.

14.

Kwok

Cho

Kim

Park

. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: Risk factors and clinical outcome: A single centre study. Lupus 2009; 18: 16–21.

15.

Klonizakis

Tselios

Sarantopoulos

et al.

ADAMTS-13 metalloprotease abnormalities in systemic lupus erythematosus: Is there a correlation with disease status?

Lupus 2013; 22: 443–452.

16.

Mannucci

Vanoli

Forza

Canciani

Scorza

. Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis). Haematologica 2003; 88: 914–918.

17.

Rieger

Mannucci

Kremer Hovinga

et al.

ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 2005; 106: 1262–1267.

18.

Moore

Hayward

Warkentin

Kelton

. Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. Blood 2001; 98: 1842–1846.

19.

Al-Awadhi

Jadaon

Al-Jafar

Al-Wazzan

. ADAMTS-13 antigen and activity levels in thrombocytopenic disorders including thrombotic thrombocytopenic purpura in Kuwait. Acta Haematol 2011; 125: 160–166.

20.

Lancellotti

De Filippis

Pozzi

et al.

Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13: A new prothrombotic mechanism in diseases associated with oxidative stress. Free Radic Biol Med 2010; 48: 446–456.

21.

Rayes

Roumenina

Dimitrov

et al.

The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status. Blood 2014; 123: 121–125.

22.

Tati

Kristoffersson

Ståhl

et al.

Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy. J Immunol 2013; 191: 2184–2193.

23.

Weening

D’Agati

Schwartz

et al.

The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65: 521–530.

24.

Hochberg

. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725–1725.

25.

Liang

Socher

Larson

Schur

. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 1107–1118.

26.

Bombardier

Gladman

Urowitz

Caron

Chang

. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630–640.

27.

Wang

Tan

Song

Zhao

. Serum complement factor H is associated with clinical and pathological activities of patients with lupus nephritis. Rheumatology (Oxford) 2012; 51: 2269–2277.

28.

Song

Wang

et al.

Overactivation of complement alternative pathway in postpartum atypical hemolytic uremic syndrome patients with renal involvement. Am J Reprod Immunol 2015; 74: 345–356.

29.

Austin

3rd Muenz

Joyce

Antonovych

Balow

. Diffuse proliferative lupus nephritis: Identification of specific pathologic features affecting renal outcome. Kidney Int 1984; 25: 689–695.

30.

Austin

3rd Boumpas

Vaughan

Balow

. Predicting renal outcomes in severe lupus nephritis: Contributions of clinical and histologic data. Kidney Int 1994; 45: 544–550.

31.

Gombos

Makó

Cervenak

et al.

Levels of von Willebrand factor antigen and von Willebrand factor cleaving protease (ADAMTS13) activity predict clinical events in chronic heart failure. Thromb Haemost 2009; 102: 573–580.

32.

Findlay

Smith

Lee

et al.

Validation of immunoassays for bioanalysis: A pharmaceutical industry perspective. J Pharm Biomed Anal 2000; 21: 1249–1273.

33.

Kotzin

. Systemic lupus erythematosus. Cell 1996; 85: 303–306.

34.

Perutelli

Amato

Calevo

Molinari

. Von Willebrand factor cleaving protease (ADAMTS-13) activity is stable in a set of plasma samples after prolonged storage at –80 degrees C. Thromb Res 2005; 116: 443–445.

35.

Appel

Pirani

D’Agati

. Renal vascular complications of systemic lupus erythematosus. J Am Soc Nephrol 1994; 4: 1499–1515.

36.

Descombes

Droz

Drouet

Grünfeld

Lesavre

. Renal vascular lesions in lupus nephritis. Medicine (Baltimore) 1997; 76: 355–368.

37.

Schwameis

Schörgenhofer

Assinger

Steiner

Jilma

. VWF excess and ADAMTS13 deficiency: A unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP. Thromb Haemost 2015; 113: 708–718.

38.

Chu

Song

Zhao

. Noninflammatory necrotizing vasculopathy in lupus nephritis: A single-center experience. Lupus 2014; 23: 20–30.

39.

Bernardo

Ball

Nolasco

Moake

Dong

. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 2004; 104: 100–106.

40.

Feng

Liang

Cruz

et al.

The interaction between factor H and Von Willebrand factor. PLoS One 2013; 8: e73715–e73715.

41.

Réti

Farkas

Csuka

et al.

Complement activation in thrombotic thrombocytopenic purpura. J Thromb Haemost 2012; 10: 791–798.

42.

Ruiz-Torres

Casiraghi

Galbusera

et al.

Complement activation: The missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thromb Haemost 2005; 93: 443–452.

43.

Song

Wang

et al.

The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther 2013; 15: R12–R12.

44.

Peyvandi

Scully

Kremer Hovinga

et al.

Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2016; 374: 511–522.

45.

Tersteeg

Schiviz

De Meyer

et al.

Potential for recombinant ADAMTS13 as an effective therapy for acquired thrombotic thrombocytopenic purpura. Arterioscl Thromb Vasc Biol 2015; 35: 2336–2342.